{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:34:00Z","timestamp":1792528440731,"version":"4.5.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Melanoma has long served as a paradigm for cancer immunotherapy due to its high immunogenicity and the transformative impact of immune checkpoint blockade. However, durable clinical benefit remains confined to a subset of patients, with primary and acquired resistance remaining common. This plateau highlights a central unresolved question: how melanoma evades immune-mediated elimination despite reinvigorated antitumor immunity. Immune escape in melanoma cannot be fully explained by defects in antigen presentation, interferon signaling, or checkpoint regulation alone. Increasing evidence identifies tumor-intrinsic metabolic reprogramming as a dominant driver of immune dysfunction. By rewiring glucose, amino acid, lipid, and mitochondrial metabolism, melanoma cells create a metabolically restrictive microenvironment that suppresses effector T and NK cell function while favoring regulatory and myeloid immunosuppressive states through nutrient competition, inhibitory metabolite accumulation, and metabolite-driven signaling. In this Review, we synthesize recent advances establishing metabolic reprogramming as an organizing principle of immune escape in melanoma. We integrate how tumor metabolic programs shape immune cell fate, function, and spatial organization, and how metabolic crosstalk between tumor and immune compartments generates immune-resistant niches that persist despite checkpoint blockade. We further discuss emerging therapeutic strategies that target metabolic vulnerabilities, alone or in rational combination with immunotherapy, to overcome resistance by reconditioning the metabolic context of antitumor immunity. By reframing metabolism as a governing axis rather than a secondary hallmark of melanoma, this Review provides a conceptual and translational framework for the development of mechanism-guided immunotherapies with durable clinical impact.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1805144","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:36:49Z","timestamp":1777354609000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic reprogramming as a driver of immune escape in melanoma: implications for immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Hong","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Traditional Chinese Medicine Internal Medicine, Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine Internal Medicine, Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.11.003","article-title":"Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity","volume":"43","author":"Qiu","year":"2025","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41420-025-02617-3","article-title":"Metabolic reprogramming in melanoma therapy","volume":"11","author":"Shen","year":"2025","journal-title":"Cell Death Discov"},{"key":"B5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2025.01.009","article-title":"Decoding melanoma's cellular mosaic to unlock immunotherapy potential","volume":"35","author":"Pozniak","year":"2025","journal-title":"Trends Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2025.01.021","article-title":"Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma","volume":"37","author":"Borbenyi-Galambos","year":"2025","journal-title":"Cell Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: Towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08439-0","article-title":"Immune evasion through mitochondrial transfer in the tumour microenvironment","volume":"638","author":"Ikeda","year":"2025","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02082-x","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002954","article-title":"Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2\/mTORC1\/p62 axis in tumor-infiltrating CD8T lymphocytes","volume":"9","author":"Nishida","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03054-1","article-title":"Anti-tumour immunity induces aberrant peptide presentation in melanoma","volume":"590","author":"Bartok","year":"2021","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01304-w","article-title":"Targeting metabolism to enhance immunotherapy within tumor microenvironment","volume":"45","author":"Liang","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7113","DOI":"10.1038\/s41467-022-34907-0","article-title":"BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS(Q61)-mutated melanomas to targeted therapy","volume":"13","author":"McGrail","year":"2022","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12964-025-02173-4","article-title":"Unraveling the role of hypoxia-inducible factors in cutaneous melanoma: from mechanisms to therapeutic opportunities","volume":"23","author":"Bellazzo","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007146","article-title":"Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis","volume":"11","author":"Liu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.02.024","article-title":"Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy","volume":"27","author":"Cascone","year":"2018","journal-title":"Cell Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177606","article-title":"Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models","volume":"134","author":"Verma","year":"2024","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00721-w","article-title":"Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma","volume":"5","author":"Mahmood","year":"2024","journal-title":"Nat Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41419-024-07122-6","article-title":"Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment","volume":"15","author":"Zheng","year":"2024","journal-title":"Cell Death Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12967-024-05033-w","article-title":"Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy","volume":"22","author":"Miao","year":"2024","journal-title":"J Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01999-3","article-title":"Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism","volume":"25","author":"Peralta","year":"2024","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02519-z","article-title":"Lactate: elucidating its indispensable role in human health","volume":"25","author":"Zhang","year":"2026","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395786","article-title":"Lactate and lactylation in macrophage metabolic reprogramming: current progress and outstanding issues","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.044","article-title":"Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1\/PD-L1 blockade therapy-resistant tumor","volume":"33","author":"Oh","year":"2025","journal-title":"Mol Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12943-024-02164-y","article-title":"Molecular mechanisms and therapeutic significance of tryptophan metabolism and signaling in cancer","volume":"23","author":"Yan","year":"2024","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006728","article-title":"Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2\/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes","volume":"11","author":"Solvay","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2204753","article-title":"Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III\/IV melanoma","volume":"12","author":"Oldan","year":"2023","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.011","article-title":"Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment","volume":"186","author":"Bender","year":"2023","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169160","article-title":"Tryptophan: its metabolism along the kynurenine, serotonin, and indole pathway in Malignant melanoma","volume":"23","author":"Hubkova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00850-9","article-title":"IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor","volume":"22","author":"Liu","year":"2021","journal-title":"Nat Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.09.002","article-title":"Oncogene-dependent sloppiness in mRNA translation","volume":"81","author":"Champagne","year":"2021","journal-title":"Mol Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.03.007","article-title":"Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence","volume":"507","author":"Grillo","year":"2021","journal-title":"Cancer Lett"},{"key":"B35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41419-023-05981-z","article-title":"STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41419-023-05828-7","article-title":"TFEB inhibition induces melanoma shut-down by blocking the cell cycle and rewiring metabolism","volume":"14","author":"Ariano","year":"2023","journal-title":"Cell Death Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202002404","article-title":"Dose-dependent carbon-dot-induced ROS promote uveal melanoma cell tumorigenicity via activation of mTOR signaling and glutamine metabolism","volume":"8","author":"Ding","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1485006","article-title":"Developing a prognostic model of glutamine metabolism-related genes associated with clinical features and immune status in melanoma","volume":"15","author":"Hu","year":"2025","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114988","article-title":"ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis","volume":"43","author":"Hlavaty","year":"2024","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241426","article-title":"Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophages","volume":"222","author":"Li","year":"2025","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12951-023-01979-z","article-title":"CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling","volume":"21","author":"Ai","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1038\/s41467-020-17181-w","article-title":"Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth","volume":"11","author":"Ishak Gabra","year":"2020","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","first-page":"18741","DOI":"10.1038\/s41598-025-03446-1","article-title":"Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor OATD-02 boosts anticancer immunity","volume":"15","author":"Grzybowski","year":"2025","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1461455","article-title":"Metabolic pathways fueling the suppressive activity of myeloid-derived suppressor cells","volume":"15","author":"Goldmann","year":"2024","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00549-7","article-title":"Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities","volume":"12","author":"Qian","year":"2024","journal-title":"biomark Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147628","article-title":"Enhancing the effect of tumor necrosis factor-related apoptosis-inducing ligand signaling and arginine deprivation in melanoma","volume":"22","author":"Wu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-022-12218-0","article-title":"Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19alpha protein","volume":"106","author":"Lee","year":"2022","journal-title":"Appl Microbiol Biotechnol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12151","article-title":"Degradation of AMPK-alpha1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation","volume":"11","author":"Li","year":"2017","journal-title":"Mol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5683","article-title":"PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity","volume":"12","author":"Kim","year":"2020","journal-title":"Sci Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-1082","article-title":"PRMT1 inhibition activates the interferon pathway to potentiate antitumor immunity and enhance checkpoint blockade efficacy in melanoma","volume":"84","author":"Tao","year":"2024","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110582","article-title":"PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade","volume":"38","author":"Srour","year":"2022","journal-title":"Cell Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI95410","article-title":"SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth","volume":"128","author":"Tamiya","year":"2018","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41467-021-21960-4","article-title":"Citrullination of pyruvate kinase M2 by PADI1 and PADI3 regulates glycolysis and cancer cell proliferation","volume":"12","author":"Coassolo","year":"2021","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404585","article-title":"Rbfox3 promotes transformation of MDSC-like tumor cells to shape immunosuppressive microenvironment","volume":"12","author":"Li","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1500","article-title":"The lipogenic regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses ferroptosis","volume":"11","author":"Hong","year":"2021","journal-title":"Cancer Discov"},{"key":"B57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12944-025-02597-4","article-title":"TNFalpha activation of the PLEKHA5-FCRLA axis disturbs lipid metabolism, leading to the progression of cutaneous Malignant melanoma","volume":"24","author":"Yan","year":"2025","journal-title":"Lipids Health Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166644","article-title":"Peroxisome disruption alters lipid metabolism and potentiates antitumor response with MAPK-targeted therapy in melanoma","volume":"133","author":"Huang","year":"2023","journal-title":"J Clin Invest"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.927118","article-title":"Targeting of the lipid metabolism impairs resistance to BRAF kinase inhibitor in melanoma","volume":"10","author":"Vergani","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.04.001","article-title":"Stromal lipid species dictate melanoma metastasis and tropism","volume":"43","author":"Gurung","year":"2025","journal-title":"Cancer Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08258-3","article-title":"Dietary fructose enhances tumour growth indirectly via interorgan lipid transfer","volume":"636","author":"Fowle-Grider","year":"2024","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1038\/s41467-022-30490-6","article-title":"Lipid droplet degradation by autophagy connects mitochondria metabolism to Prox1-driven expression of lymphatic genes and lymphangiogenesis","volume":"13","author":"Mece","year":"2022","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1038\/s41467-023-38831-9","article-title":"Lipid droplets are a metabolic vulnerability in melanoma","volume":"14","author":"Lumaquin-Yin","year":"2023","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metab"},{"key":"B65","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41419-024-06503-1","article-title":"Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8(+) T cells","volume":"15","author":"Han","year":"2024","journal-title":"Cell Death Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz6314","article-title":"Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy","volume":"13","author":"Liu","year":"2021","journal-title":"Sci Transl Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41467-017-02186-9","article-title":"Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer","volume":"8","author":"Veglia","year":"2017","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12964-022-00849-9","article-title":"The activation of PPARgamma enhances Treg responses through up-regulating CD36\/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of TbetaRII\/IL-2Ralpha","volume":"20","author":"Miao","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm7269","article-title":"Tumor extracellular vesicle-derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming","volume":"17","author":"Ma","year":"2025","journal-title":"Sci Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008554","article-title":"Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-gamma-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors","volume":"12","author":"Tao","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35897","article-title":"Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies","volume":"131","author":"Kim","year":"2025","journal-title":"Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202084","article-title":"A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients","volume":"219","author":"Li","year":"2022","journal-title":"J Exp Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12967-023-04200-9","article-title":"The role of mitochondria in the resistance of melanoma to PD-1 inhibitors","volume":"21","author":"Du","year":"2023","journal-title":"J Transl Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0365-3","article-title":"Enforced PGC-1alpha expression promotes CD8 T cell fitness, memory formation and antitumor immunity","volume":"18","author":"Dumauthioz","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add2712","article-title":"Lactate oxidase nanocapsules boost T cell immunity and efficacy of cancer immunotherapy","volume":"15","author":"Cao","year":"2023","journal-title":"Sci Transl Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12967-025-07272-x","article-title":"Lactate at the crossroads of tumor metabolism and immune escape: a new frontier in cancer therapy","volume":"23","author":"Dong","year":"2025","journal-title":"J Transl Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178241","article-title":"Therapeutic potential of glutaminase inhibition targeting metabolic adaptations in resistant melanomas to targeted therapy","volume":"26","author":"Soumoy","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12943-025-02460-1","article-title":"Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2302878120","article-title":"CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing","volume":"120","author":"Liu","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa177","article-title":"Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases","volume":"3","author":"Fischer","year":"2021","journal-title":"Neuro-Oncol Adv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15020050","article-title":"Targeting metabolic vulnerabilities to combat drug resistance in cancer therapy","volume":"15","author":"Khan","year":"2025","journal-title":"J Pers Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1428802","article-title":"Metabolic modulation of melanoma enhances the therapeutic potential of immune checkpoint inhibitors","volume":"14","author":"Gurel","year":"2024","journal-title":"Front Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41467-025-56392-x","article-title":"MCT1 lactate transporter blockade re-invigorates anti-tumor immunity through metabolic rewiring of dendritic cells in melanoma","volume":"16","author":"Niveau","year":"2025","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01544-x","article-title":"A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011706","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial","volume":"13","author":"Block","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01224-z","article-title":"Regulation of CD8+ T cells by lipid metabolism in cancer progression","volume":"21","author":"Tang","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1805144\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:36:50Z","timestamp":1777354610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1805144\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2026.1805144"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1805144","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1805144"}}